01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

Day ML, Wu S, Basler JW (1993) Prostatic nerve growth factor
inducible A gene binds a novel element in the retinoblastoma
gene promoter. Cancer Res 53, 5597-5599.
de los Santos C, Rosen M, Patel D (1989) NMR studies of DNA
(R +
) n.(Y -
) n.(Y +
) n triple helices in solution: imino and amino
proton markers of T.A.T and C.G.C + base-triple formation.
Biochemistry 28, 7282-7289.
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, and
Williams LT (1992) The fms-like tyrosine kinase, a receptor
for vascular endothelial growth factor. Science 255, 989-991.
Deb S, Jackson CT, Subler MA, and Martin DW (1992)
Modulation of cellular and viral promoters by mutant human
p53 proteins found in tumor cells. J Virol 66, 6164-6170.
Deb SP, Muñoz RM, Brown DR, Subler MA, and Deb S (1994)
Wild-type human p53 activates the human epidermal growth
factor receptor promoter. Oncogene 9, 1341-1349.
Debbas, M. and White, E. (1993) Wild-type p53 mediates
apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7,
546-554.
DeCaprio, J.A. , Ludlow, J.W., Lynch, D., Furukawa, Y., Griffin,
J., Piwnica-Worms, H., Huang, C.-M. and Livingston, D.M.
(1989) The product of the retinoblastoma susceptibility gene
has properties of a cell cycle regulatory element. Cell 58,
1085-1095.
Deglon N, Heyd B, Tan SA, Joseph JM, Zurn AD, Aebischer P
(1996) Central nervous system delivery of recombinant
ciliary neurotrophic factor by polymer encapsulated
differentiated C2C12 myoblasts. Hum Gene Ther 7, 2135-
2146.
Delort JP and Capecchi MR (1996) TAXI/UAS: a molecular
switch to control expression of genes in vivo. Human Gene
Ther 7, 809-820.
DeLuca NA, and Schaffer PA (1987) Activities of herpes
simplex virus type 1 (HSV-1) ICP4 genes specifying
nonsense peptides. Nucleic Acids Res 15, 4491-4511.
Dematteo RP, McClane SJ, Fisher K, Yeh H, Chu G, Burke C,
Raper SE (1997) Engineering tissue-specific expression of a
recombinant adenovirus: selective transgene transcription in
the pancreas using the amylase promoter. J Surg Res 72,
155-161.
Deppert W (1994) The yin and yang of p53 in cellular
proliferation. Sem Cancer Biol 5, 187-202.
Devlin JJ, Panganiban LC, Devlin PE (1990) Random peptide
libraries: A source of specific binding protein molecules.
Science 249, 404-406.
Dhawan J, Pan LC, Pavlath GK, Travis MA, Lanctot AM, Blau
HM (1991) Systemic delivery of human growth hormone by
injection of genetically engineered myoblasts. Science 254,
1509-1512.
Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt
M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH
(1990) p53 functions as a cell cycle control protein in
osteosarcomas. Mol Cell Biol 10, 5772-5781.
Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt
M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH
(1990) p53 functions as a cell cycle control protein in
osteosarcomas. Mol Cell Biol 10, 5772-5781.
Gene Therapy and Molecular Biology Vol 1, page 137
137
Dimaio JM, Clary BM, Via DF, Coveney E, Papas TN, and
Lyerly HK (1994) Directed enzyme pro-drug gene therapy
for pancreatic cancer in vivo. Surgery 116, 205-213.
Dinjens WN, van der Weiden MM, Schroeder FH, Bosman FT,
and Trapman J (1994) Frequency and characterization of p53
mutations in primary and metastatic human prostate cancer.
Int J Cancer 56, 630-633.
Dion LD, Goldsmith KT, Strong TV, Bilbao G, Curiel DT,
Garver RI Jr (1996) E1A RNA transcripts amplify
adenovirus-mediated tumor reduction. Gene Ther 3, 1021-
1025.
Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M,
Finlay C, Levine AJ: Gain of function mutations in p53.
Nature Genet 4: 42-45, 1993.
Doll RF, Crandall JE, Dyer CA, Aucoin JM, Smith FI (1996)
Comparison of promoter strengths on gene delivery into
mammalian brain cells using AAV vectors. Gene Ther 3,
437-447.
Donehower LA, Harvey M, Slagle BL, McArthur MJ,
Montgomery CAJr, Butel JS, Bradley A (1992) Mice
deficient for p53 are developmentally normal but susceptible
to spontaneous tumours. Nature 356, 215-221.
Dong JY, Fan PD, Frizzell RA (1996) Quantitative analysis of
the packaging capacity of recombinant adeno-associated
virus. Hum Gene Ther 7, 2101-2112.
Dong Z, Kumar R, Yang X, Fidler IJ (1997) Macrophagederived
metalloelastase is responsible for the generation of
angiostatin in Lewis lung carcinoma. Cell 88, 801-810.
Doorbar J, Winter G (1994) Isolation of a peptide antagonist to
the thrombin receptor using phage display. J Mol Biol 244,
361-369.
Dorai T, Olsson CA, Katz AE, Buttyan R (1997) Development
of a hammerhead ribozyme against bcl-2. I. Preliminary
evaluation of a potential gene therapeutic agent for hormonerefractory
human prostate cancer. Prostate 32, 246-258.
Dougherty JP, Wisniewski R, Yang SL, Rhode BW, Temin HM
(1989) New retrovirus helper cells with almost no nucleotide
sequence homology to retrovirus vectors. J Virol 63, 3209-
3212.
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose
K, Jackson V, Hamada H, Pardoll D, Mulligan R (1993)
Vaccination with irradiated tumor cells engineered to secrete
murine granulocyte-macrophage colony-stimulating factor
stimulates potent, specific, and long-lasting anti-tumor
immunity. Proc Natl Acad Sci USA 90, 3539-3543.
Drazan KE, Shen XD, Csete ME, Zhang WW, Roth JA, Busuttil
RW, Shaked A (1994) In vivo adenoviral-mediated human
p53 tumor suppressor gene transfer and expression in rat
liver after resection. Surgery 116, 197-203.
Duan L, Zhu M, Bagasra O, Pomerantz RJ (1995) Intracellular
immunization against HIV-1 infection of human T
lymphocytes: Utility of anti-rev single-chain variable
fragments. Hum Gene Ther 6, 1561-1573.
Duan L, Zhu M, Ozaki I, Zhang H, Wei DL, Pomerantz RJ
(1997) Intracellular inhibition of HIV-1 replication using a
dual protein- and RNA-based strategy. Gene Ther 4, 533-
543.